Dermapharm Holding SE (DMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dermapharm Holding SE (DMP) has a cash flow conversion efficiency ratio of 0.054x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€39.49 Million ≈ $46.17 Million USD) by net assets (€735.17 Million ≈ $859.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Dermapharm Holding SE net asset quality index to measure how much of total assets are equity-financed.
Dermapharm Holding SE - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Dermapharm Holding SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Dermapharm Holding SE (DMP) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Dermapharm Holding SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dermapharm Holding SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
-0.081x |
|
Hillenbrand Inc
NYSE:HI
|
-0.019x |
|
Henan Dayou Energy Co Ltd
SHG:600403
|
0.002x |
|
Arcplus Group PLC
SHG:600629
|
0.035x |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
|
-0.062x |
|
Jinyu Bio-Technology Co Ltd
SHG:600201
|
0.018x |
|
Shanghai Huafon Aluminium Corp
SHG:601702
|
-0.011x |
|
Liberty Media Corporation Series A Liberty Formula One Common Stock
NASDAQ:FWONA
|
0.042x |
Annual Cash Flow Conversion Efficiency for Dermapharm Holding SE (2014–2025)
The table below shows the annual cash flow conversion efficiency of Dermapharm Holding SE from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Dermapharm Holding SE stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €701.83 Million ≈ $820.51 Million |
€181.51 Million ≈ $212.21 Million |
0.259x | -21.88% |
| 2024-12-31 | €608.29 Million ≈ $711.16 Million |
€201.38 Million ≈ $235.43 Million |
0.331x | -17.77% |
| 2023-12-31 | €545.05 Million ≈ $637.22 Million |
€219.42 Million ≈ $256.53 Million |
0.403x | -25.70% |
| 2022-12-31 | €532.49 Million ≈ $622.54 Million |
€288.53 Million ≈ $337.33 Million |
0.542x | +8.18% |
| 2021-12-31 | €499.83 Million ≈ $584.36 Million |
€250.37 Million ≈ $292.71 Million |
0.501x | +24.02% |
| 2020-12-31 | €324.58 Million ≈ $379.47 Million |
€131.10 Million ≈ $153.27 Million |
0.404x | +14.20% |
| 2019-12-31 | €284.49 Million ≈ $332.60 Million |
€100.61 Million ≈ $117.63 Million |
0.354x | -43.08% |
| 2018-12-31 | €256.08 Million ≈ $299.39 Million |
€159.13 Million ≈ $186.04 Million |
0.621x | -47.21% |
| 2017-12-31 | €73.69 Million ≈ $86.15 Million |
€86.74 Million ≈ $101.40 Million |
1.177x | -6.78% |
| 2016-12-31 | €60.81 Million ≈ $71.09 Million |
€76.78 Million ≈ $89.76 Million |
1.263x | +38.98% |
| 2015-12-31 | €44.44 Million ≈ $51.96 Million |
€40.38 Million ≈ $47.20 Million |
0.909x | -43.05% |
| 2014-12-31 | €34.01 Million ≈ $39.76 Million |
€54.26 Million ≈ $63.43 Million |
1.595x | -- |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers br… Read more